Financial Performance - The company's operating revenue for Q1 2023 was CNY 206,156,004.83, representing a year-on-year increase of 1.20%[4] - The net profit attributable to shareholders for Q1 2023 was CNY 62,610,490.08, reflecting a growth of 6.13% compared to the same period last year[4] - The basic earnings per share for Q1 2023 was CNY 0.32, which is an increase of 6.67% year-on-year[5] - Total operating revenue for Q1 2023 was CNY 206,156,004.83, a slight increase of 0.21% compared to CNY 203,720,149.88 in Q1 2022[19] - Net profit for Q1 2023 reached CNY 62,610,490.08, representing an increase of 2.47% from CNY 59,142,082.00 in Q1 2022[20] - Earnings per share for Q1 2023 were CNY 0.32, compared to CNY 0.30 in Q1 2022, reflecting a growth of 6.67%[20] - Other comprehensive income after tax for Q1 2023 was CNY 5,723,141.98, compared to CNY 4,875,301.97 in Q1 2022, indicating a growth of 17.38%[20] Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 2,984,851,552.15, up 4.50% from the end of the previous year[5] - As of March 31, 2023, the total assets of Zhejiang Shuxian Valley Pharmaceutical Co., Ltd. amounted to CNY 2,984,851,552.15, an increase from CNY 2,856,189,559.66 at the end of 2022, reflecting a growth of approximately 4.5%[14] - The company's cash and cash equivalents reached CNY 1,624,310,541.31, up from CNY 1,524,712,390.54 at the end of 2022, indicating an increase of about 6.5%[14] - Inventory levels increased to CNY 164,854,744.62 from CNY 147,756,333.74, representing a rise of approximately 11.6%[14] - The total liabilities of the company increased to CNY 951,224,146.27 from CNY 890,354,337.34, reflecting a growth of about 6.8%[15] - Total liabilities as of Q1 2023 were CNY 1,010,947,011.71, an increase of 6.34% from CNY 950,667,244.96 in Q1 2022[19] Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 78,770,447.68, showing a decrease of 3.13% compared to the previous year[4] - Cash flow from operating activities for Q1 2023 was CNY 78,770,447.68, a decrease of 3.09% from CNY 81,311,500.62 in Q1 2022[21] - Cash inflow from operating activities totaled CNY 242,844,419.45 in Q1 2023, an increase of 8.14% from CNY 224,529,100.62 in Q1 2022[21] - In Q1 2023, the net cash flow from investing activities was -$48,674,579.89, compared to -$47,430,058.40 in the previous year[23] - The total cash inflow from financing activities was $302,925,760.00, with cash outflow totaling $308,423,477.02, resulting in a net cash flow of -$5,497,717.02[23] - The cash generated from financing activities included $187,925,760.00 from borrowings and $115,000,000.00 from other financing activities[23] - The net increase in cash and cash equivalents for Q1 2023 was $24,598,150.77, compared to $27,686,518.37 in the previous year[23] Shareholder Information - The company reported a total of 15,244 common shareholders at the end of the reporting period[10] - The top shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., holds 28.76% of the shares, amounting to 56,711,239 shares[10] Other Financial Metrics - The weighted average return on equity for Q1 2023 was 3.23%, a decrease of 0.34 percentage points year-on-year[5] - The total current liabilities increased to CNY 531,550,902.54 from CNY 477,765,151.63, reflecting a growth of about 11.2%[15] - The company's long-term investments in equity increased slightly to CNY 5,988,270.17 from CNY 5,927,692.09, showing a growth of approximately 1.0%[14] - The non-current assets totaled CNY 1,015,937,901.80, up from CNY 994,178,202.27, indicating an increase of about 2.5%[15] - The company's accounts receivable decreased to CNY 88,648,652.43 from CNY 113,660,007.77, a decline of approximately 22.0%[14] - Research and development expenses for Q1 2023 were CNY 11,429,365.94, an increase of 5.68% from CNY 10,816,003.23 in Q1 2022[19] Prepayments - The company experienced a significant increase in prepayments, with a rise of 117.20% in advance payments received during the reporting period[8] - The company reported a significant increase in prepayments to CNY 15,193,252.07 from CNY 13,965,241.53, which is an increase of approximately 8.8%[14] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2023[25]

Financial Performance - The company's operating revenue for 2022 was approximately CNY 829.07 million, representing an increase of 8.07% compared to CNY 767.14 million in 2021[25]. - Net profit attributable to shareholders of the listed company reached approximately CNY 277.78 million, a significant increase of 38.32% from CNY 200.83 million in the previous year[25]. - The net profit after deducting non-recurring gains and losses was approximately CNY 253.18 million, up 27.39% from CNY 198.75 million in 2021[25]. - The company's total assets increased by 45.54% to approximately CNY 2.86 billion from CNY 1.96 billion in 2021[25]. - The weighted average return on net assets rose to 16.07%, an increase of 2.53 percentage points from 13.54% in the previous year[26]. - Basic earnings per share for 2022 were CNY 1.43, reflecting a 36.19% increase from CNY 1.05 in 2021[26]. - The cash flow from operating activities for 2022 was approximately CNY 341.28 million, an increase of 15.03% compared to CNY 296.70 million in 2021[25]. - The company's net assets attributable to shareholders reached approximately CNY 1.91 billion, up 17.65% from CNY 1.62 billion at the end of 2021[25]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - All board members attended the board meeting, ensuring the integrity of the annual report[11]. - The company confirms that there are no non-operating fund occupations by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures in providing guarantees[9]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with relevant laws and regulations[190]. - The supervisory board is composed of 3 members, maintaining independence and oversight of the company's operations and management[190]. - The company strictly adheres to regulations regarding related party transactions, ensuring fairness and compliance in pricing and decision-making processes[191]. - There were no instances of non-operating fund occupation by the controlling shareholder or its affiliates during the reporting period[191]. Market Expansion and Strategy - The company plans to continue expanding its market presence and invest in new product development to drive future growth[24]. - The company signed contracts with 14 new city agents, expanding its sales network across multiple regions including Kunming, Guiyang, and Wuhan[36]. - The company launched a new marketing strategy that includes high-speed train advertisements, enhancing brand visibility across 18 provinces and regions[36]. - The company plans to expand its market presence outside Zhejiang province and increase efforts in community promotion and recruiting distributors for spore powder tablets[109]. - The company is focusing on the development of high-quality traditional Chinese medicine varieties, including Lingzhi and Dendrobium, supported by a clinical efficacy database[166]. - The company is actively pursuing key technology upgrades and digital transformation projects to enhance operational efficiency and product quality[175]. - The company aims to implement a development strategy centered on innovation in biotechnology and the cultivation of rare medicinal materials[165]. Research and Development - The company has a research and development team of 145 people, including 46 with senior titles and 11 PhDs[53]. - Research and development expenses amounted to 47.82 million yuan, a decrease of 5.90% from the previous year[98]. - The company is focusing on improving technology processes, developing new strains, and enhancing production equipment as part of its R&D strategy[138]. - The company has several ongoing R&D projects, including traditional Chinese medicine formulations aimed at various health conditions[140]. - The company is developing a new product, "寿仙谷牌铁皮石斛饮料," aimed at enhancing immunity, which is currently in the registration process[141]. - The company has maintained a consistent R&D investment strategy over the past three years, with a slight decrease in the percentage of revenue allocated to R&D[139]. - The company has registered multiple new health food products, including "Shouxiangu Brand Iron Skin Dendrobium Drink" and "Shouxiangu Brand Monkey Head Mushroom Dendrobium Huangqi Tablets"[146]. Product Development and Innovation - The company’s proprietary processing technology for Ganoderma lucidum has been patented in seven countries, showcasing its innovation in product development[38]. - The company’s new product lines, including "Xianhu 1," "Xianhu 2," and "Xianhu 3," have received national variety protection, indicating successful innovation in product offerings[38]. - The company has developed a rare medicinal plant germplasm resource bank, collecting 117 Dendrobium germplasm resources and achieving high survival rates and yields through modern breeding techniques[86]. - The company’s "Xianhua 1", "Xianhua 2", and "Xianhua 3" Ganoderma varieties have been recognized for their strong resistance and high active ingredient content, contributing to its competitive advantage[84]. - The company is actively working on the safety evaluation and pharmacological research of its traditional Chinese medicine products[140]. Social Responsibility and Community Engagement - The company is actively involved in social responsibility initiatives, including donations of health products to frontline medical workers[57]. - The company has implemented a "common prosperity model" that integrates rental income, labor, cooperative product sales, and technology promotion, which has received high praise from government bodies[57]. - The company has been awarded multiple honors, including being named a national science popularization education base and a green factory in Zhejiang Province[58]. Financial Management and Investments - The company’s investment activities generated a net cash flow of -85.39 million yuan, a significant improvement from -233.72 million yuan in the previous year[98]. - Cash and cash equivalents rose by 124.89% to ¥1,524,712,390.54, mainly due to funds received from the issuance of convertible bonds[128]. - The company’s bonds payable surged by 371.00% to ¥412,589,185.71, resulting from the issuance of convertible bonds during the reporting period[130]. - The company has proposed a plan for the public issuance of convertible bonds, with a feasibility analysis conducted on the use of raised funds[194]. Human Resources and Management - The total pre-tax remuneration for executives during the reporting period amounted to 452.55 million yuan[197]. - The company has implemented a "Four Eagles" human resources action plan to strengthen performance assessment and talent acquisition, focusing on attracting passionate and creative young talent[177]. - The management team has experienced changes, with several executives leaving and new appointments made to strengthen leadership[198]. - The leadership team includes professionals with extensive experience in finance, administration, and research, which is expected to drive innovation[200]. Future Outlook - Future guidance indicates a positive outlook for revenue growth and market expansion in the coming years[198]. - The company aims for a revenue growth rate and net profit growth rate of over 20% year-on-year in 2023[170]. - The company is committed to improving shareholder value through effective management and strategic initiatives[198].

2022 年第三季度报告 单位：元 币种：人民币 1 / 13 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------|----------------------------------------|----------------|------ ...

Financial Performance - The company reported a half-year performance summary with no significant risks impacting operations[6]. - The company achieved a net profit attributable to shareholders of RMB 82.02 million, a year-on-year increase of 49.13%[22]. - The basic earnings per share increased to RMB 0.42, representing a growth of 44.83% compared to the same period last year[22]. - Operating revenue for the first half of the year was RMB 349.53 million, up 10.09% from RMB 317.49 million in the previous year[23]. - The net cash flow from operating activities reached RMB 184.90 million, reflecting a growth of 30.07% year-on-year[23]. - The company’s total assets increased by 4.31% to RMB 2.05 billion compared to the end of the previous year[23]. - The weighted average return on net assets rose to 4.96%, an increase of 1.00 percentage points from the previous year[22]. - The company reported a total revenue of 29,763.49 million RMB for the first half of 2022, with a gross margin of 86.31%[91]. - The company achieved an operating profit of ¥82,873,711.88, up from ¥56,397,609.83, reflecting a growth of 46.8% year-over-year[170]. - The company reported a total comprehensive income of ¥86,813,197.44 for the first half of 2022, compared to ¥58,252,348.06 in the same period of 2021, indicating a growth of 48.9%[171]. Corporate Governance - The board of directors confirmed the authenticity and completeness of the financial report[4]. - The report is unaudited, ensuring transparency in financial disclosures[4]. - The company has established an information management system to optimize market operations, resulting in improved profit margins[69]. - The company has committed to transparency and adherence to corporate governance standards in its operations[126]. - The company has maintained compliance with legal regulations regarding related party transactions and has ensured fair trading practices[126]. Risk Management - The management has outlined potential risks in the "Management Discussion and Analysis" section[6]. - The company emphasizes the importance of investor awareness regarding investment risks[5]. - The company faces risks related to natural disasters affecting the supply of key raw materials like Lingzhi and Dendrobium, which could impact production[98]. - The company has a risk of production qualification being revoked or not renewed, which could adversely affect operations[100]. Market Strategy and Expansion - The company plans to continue expanding its product line, focusing on high-quality traditional Chinese medicine and health products[28]. - The company maintains a strategy of optimizing its industrial layout and enhancing its core competitive advantages in the market[28]. - The company aims to leverage its advantages in seed sources and full industry chain to expand sales channels and establish "Shouxiangu" as a nationally recognized brand[47]. - The company plans to expand its market presence, focusing on the development of new products and technologies in the health sector[88]. - The company has established a "full industry chain" development model for products like Lingzhi and Dendrobium, ensuring standardized cultivation from breeding to processing[51]. Research and Development - The company has developed and certified three new Dendrobium varieties: "Xianhu 1," "Xianhu 2," and "Xianhu 3," which are characterized by high survival rates and strong resistance[57]. - The company has developed a patented "four lows and one high" ultrasonic low-temperature airflow breaking technology, significantly improving product safety and efficacy[62]. - The company has initiated several clinical trials related to its Ganoderma lucidum spore powder, including studies on its effects on immune function and its application in cancer treatment[72]. - The company received three new invention patents during the reporting period, enhancing its research and development capabilities[70]. Social Responsibility - The company actively donated products to frontline medical personnel during the COVID-19 pandemic, including donations to various hospitals and organizations[122]. - The "Shouxiangu Caring for Tumor Students" public welfare initiative has entered its fifth season, highlighting the company's commitment to social responsibility[122]. - The company has been recognized for its contributions to technological innovation and rural revitalization efforts by various provincial departments[121]. Shareholder Information - The company distributed a cash dividend of RMB 4.05 per 10 shares, totaling RMB 60.32 million, and increased its total share capital to 197.20 million shares[23]. - The company plans to issue convertible bonds, with a feasibility analysis report presented for shareholder approval[111]. - The total share capital after the distribution is 197,195,916 shares, reflecting an increase due to the capital reserve conversion[138]. - The company has no significant litigation or arbitration matters during the reporting period[129]. Financial Health - The company has maintained a strong debt repayment capability, having repaid all bank loans on time and in full without any overdue debts[159]. - The company’s credit rating remains stable at "AA-" for both the company and the convertible bonds, with no significant changes in creditworthiness[158]. - The total liabilities increased to ¥399,947,341.65 from ¥342,410,273.94, a growth of about 16.8%[164]. - The total owner's equity at the end of the current period reached approximately 1,647,038.7 million, reflecting growth in capital reserves[184].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李明焱、主管会计工作负责人及会计机构负责人（会计主管人员）祝彪保证季度报告 中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 \n变动幅度 ( ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李明焱、主管会计工作负责人及会计机构负责人（会计主管人员）祝彪保证季度报告 中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | ...

Dividend and Capital Management - The company plans to distribute a cash dividend of 4.05 CNY per 10 shares (including tax) and to increase capital by converting 3 shares for every 10 shares held[6]. - The company has committed to maintaining the distribution ratio even if there are changes in total share capital before the dividend distribution date[6]. Risk Management and Audit - The company has confirmed that there are no significant risks affecting its production and operations during the reporting period[8]. - The company has received a standard unqualified audit report from the accounting firm[5]. - The board of directors and management have ensured the accuracy and completeness of the annual report[4]. - There are no non-operational fund occupations by controlling shareholders or related parties[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The company has detailed potential risks in the "Management Discussion and Analysis" section of the report[8]. - The company has not faced any substantial risks that could impact its operations during the reporting period[8]. Financial Performance - The company achieved operating revenue of CNY 767,137,327.36 in 2021, representing a year-on-year growth of 20.61%[27]. - The net profit attributable to shareholders reached CNY 200,826,526.21, an increase of 32.37% compared to the previous year[27]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 198,751,369.45, reflecting a growth of 45.19% year-on-year[27]. - The net cash flow from operating activities was CNY 296,699,128.48, up by 15.74% from the previous year[27]. - The company's total assets at the end of 2021 were CNY 1,962,459,613.29, a 15.47% increase from the end of 2020[27]. - The net assets attributable to shareholders increased to CNY 1,619,664,568.66, marking a growth of 22.12% year-on-year[27]. - Basic earnings per share for 2021 were CNY 1.34, up 25.23% from CNY 1.07 in 2020[27]. Research and Development - The company launched 11 new research projects in 2021, with 8 successfully approved, including 2 national-level projects[41]. - The company applied for 20 patents in 2021, with 6 patents granted, including 1 foreign invention patent[42]. - The company established three major databases: phenotype library, gene bank, and chemical substance metabolism library[42]. - The company’s management and R&D team has extensive experience in the industry, ensuring a strong competitive advantage in technology and marketing[86]. - The company has focused on several key R&D projects, with the highest investment in the clinical efficacy of broken wall ganoderma spore powder for late-stage cancer patients, totaling 748.14 million RMB, which is 0.98% of operating revenue[160]. Market Expansion and Sales Strategy - The company launched new sales channels, including the establishment of Zhejiang Shouxiangu Jishi Health Development Co., Ltd. to explore national market agency systems[30]. - The company aims to innovate cloud sales through platforms like Shouxiangu Mini Programs, enhancing its market strategy[30]. - The company is actively expanding its market presence and has signed agreements for land transfer in the Shigehu area, covering 8,000 acres[47]. - The company plans to expand its market presence outside Zhejiang by increasing promotional efforts and recruiting distributors for spore powder tablets[106]. - The company aims to enhance brand awareness and product visibility through increased marketing efforts, particularly in ground promotions and customer experiences[179]. - The company aims to establish a world-class research and innovation platform for rare plant medicines, utilizing AI, big data, and IoT technologies[193]. - The company is focusing on expanding its market presence through a diversified e-commerce strategy and establishing a nationwide distribution network[194]. Product Development and Quality Control - The company has successfully developed three new products: "Shouxiangu brand Dendrobium candidum tablets," "Shouxiangu brand Dendrobium candidum and Ganoderma lucidum granules," and "Shouxiangu brand Batocera rufipennis mycelium powder," which have completed the registration process for domestic health food[43]. - The company achieved a 100% quality pass rate for traditional Chinese medicine products, including proprietary Chinese medicines, Chinese medicine pieces, health foods, and agricultural products[46]. - The company has implemented a comprehensive quality control system throughout the production process, adhering to national and international standards[85]. - The company’s organic product production management has been certified with a 100% compliance rate, ensuring high-quality raw material production and supply[46]. Sales Performance - The company’s sales revenue showed steady growth, with several regions exceeding their annual sales targets[37]. - Revenue from online sales reached CNY 185.45 million, with a year-on-year growth of 27.33%[98]. - The company maintained a stable market presence in Zhejiang Province, with sales from this region accounting for 63.45% of total revenue in 2021[105]. - The overall sales revenue for the year reached 75,999.03 million RMB, a significant increase from 62,983.81 million RMB in the previous year[169]. Investment and Financial Management - The company reported a net cash outflow from investment activities of CNY 233.72 million, indicating significant investment in growth initiatives[91]. - The total investment cash flow was -233.72 million RMB, primarily due to investments in convertible bond projects[126]. - The company has made significant equity investments, including a 28.55% stake in Yecun Investment, with a year-end balance of 2,760,000.00 RMB[185]. Marketing and Advertising - Advertising expenses increased to 19,853.92 million RMB in 2021, making up 62.09% of total sales expenses, up from 46.73% in 2019[179]. - The proportion of advertising expenses to total sales expenses has shown a consistent increase, indicating a strategic focus on marketing[179]. - The company aims to expand its internet sales channels further, leveraging platforms like Tmall and JD.com to enhance market reach[172].

2021 年第三季度报告 证券代码：603896 证券简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|-------|--------------------------------------|------------------------ ...

Group 1: Event Overview - The half-year performance briefing and investor reception event was held on September 16, 2021, to enhance corporate governance and communication with investors [2] - The event took place at two locations: the organic medicinal herb planting base in Wuyi County in the morning and the company headquarters in the afternoon [3] - A total of 45 investors attended the event, with key company personnel including Chairman and General Manager Li Mingyan and other executives present [3] Group 2: Activity Schedule - The schedule included a visit to the organic medicinal herb planting base from 10:30 to 11:30 and a visit to the company headquarters from 13:00 to 14:30 [4] - The afternoon session featured a performance report by the Secretary of the Board, Liu Guofang, and a presentation on the national promotion strategy by Li Zhenyu, General Manager of Jishi Health Development Co., Ltd. [4] Group 3: Sales and Marketing Strategies - The company plans to adopt a new sales model by recruiting regional distributors to enhance sales through established channels [5] - A diverse product range is available to cater to different consumer demographics, including high-end and low-end products [6] - Increased advertising expenses in the first half of the year were attributed to heightened promotional activities [7] Group 4: Price Control Measures - The company implements several measures to maintain its product pricing structure, including anti-counterfeiting codes and regular market price checks [7][8] - A dedicated pricing control team monitors both online and offline markets to ensure compliance with pricing agreements [8] Group 5: Future Brand Promotion - Future advertising strategies will align with distributor promotion tactics, utilizing both national and local advertising channels [9] - The company emphasizes the importance of building customer trust through distributor resources, especially for high-priced products like the Lingzhi spore powder tablets [9] Group 6: Shareholder Actions - The company has repurchased 3.58 million shares, primarily for sales and management team equity incentives [10] - Investors are advised to refer to publicly disclosed information regarding major shareholder reduction plans [10]

2021 年半年度报告 公司代码：603896 公司简称：寿仙谷 债券代码：113585 债券简称：寿仙转债 浙江寿仙谷医药股份有限公司 ZhejiangShouxianguPharmaceuticalCo.,Ltd. （浙江省武义县壶山街道商城路 10 号） 2021 年半年度报告 二〇二一年八月二十五日 1 / 164 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人李明焱、主管会计工作负责人傅华平及会计机构负责人（会计主管人员）傅华平 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的前瞻性描述不构成公司对投资者的实质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保 ...